This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. 
The costing was undertaken prospectively on a sub-group (86%) of the patient sample used in the effectiveness analysis. Resource utilisation questionnaires were available on 86% of the patients in each group.
Study sample
A total of 230 patients were invited to participate. The pre-sample size was 160 patients (80 per treatment group). This, by the log-rank test at p=0.05, gave 80% power to detect a reduction in relapse rates from 40% in one group to 20% in the other. All the patients were receiving antidepressants at a minimum dose equivalent to at least 125-mg amitriptyline. The patients were then randomised to receive clinical management alone (control group) or clinical management plus cognitive therapy (cognitive therapy group). Since cost information was available for only 77 patients in each group, the clinical analysis was performed on these patients (n=154). The two treatment groups were closely comparable on all key variables. For example, the mean age (standard deviation, SD) was about 43 years, 43.3 years (SD=11.2) in the control group (c) versus 43.2 (SD=9.8) in the cognitive therapy group (ct). About 50% were male, 47%(c) versus 54%(ct). Finally, the severity ratings were in the middle of the residual depression range, with a mean HRSD score above 12 (c: 12.2, SD=2.9; ct: 12.1, SD=2.7) and a mean BDI of 22 (c: 22.3 SD=8.0; ct: 21.9, SD=7.7).
Study design
This was a randomised controlled study, which was carried out in a single centre. The duration of the follow-up was 68 weeks (20 weeks for the treatment phase and 48 weeks for the follow-up phase).
Analysis of effectiveness
The primary health outcomes were the relapse rates for the cognitive therapy group and the control group. The analysis of the clinical outcomes was conducted on an intention to treat basis. Relapse rates were defined as either:
meeting the DSM-III-R criteria for major depressive disorder for a minimum of 1 month, and also having a score of 17 or above on the HRSD at two successive face-to-face assessments at least 1 week apart; or having residual depressive symptoms that persisted between two successive ratings 2 months apart, reaching a score of at least 13 on the HRSD on both occasions combined with a level of distress or dysfunction at which withholding additional active treatment was not justified.
Cox regression was used to analyse the relapse rates. This included, as covariates, the stratification variables used in the randomisation and other relevant demographic and clinical variables.
Information on health and social care utilisation was collected using a questionnaire adapted from the Client Service Receipt Inventory. The costs were discounted at the annual rate of 6%. The unit costs were obtained from a variety of sources, including the relevant local providers, the Personal Social Services Research Unit and the British National Formulary. The cognitive therapy costs were calculated using a cost per minute taken from the mid-point of the relevant 1998 -1999 salary scales, and included the employers' national insurance and superannuation contributions and overhead costs. The additional cost of non-face-to-face activities was estimated using a ratio provided by each therapist. A similar bottom-up approach was used to assess the unit cost of other therapies. The costs and the quantities were not reported separately. The prices used were for 1998 -1999.
Statistical analysis of costs
The results of the cost analysis were reported as mean (median) values with SDs and as mean differences with 95% CIs. A non-parametric bootstrapping method (1,000 replications) was performed to test the robustness of the parametric assumptions on mean differences in the costs, and then parametric CIs were reported. Since the fully completed resource utilisation questionnaires were only available for 65% of the patients, the analysis imputed the missing assessments by using the last value carried forward at the previous assessment.
Indirect Costs
The indirect costs were not assessed.
Currency

UK pounds sterling ().
Sensitivity analysis
A one-way sensitivity analysis was carried out on the method of handling the missing data. Two alternative imputation methods were used, mean imputation and multiple imputation.
Estimated benefits used in the economic analysis
Not applicable.
Cost results
Two separate analyses of the total costs were undertaken. First, the direct costs were considered but the additional costs of cognitive therapy were excluded. The second analysis included the cognitive therapy costs in the cost analysis.
The mean direct health care costs (excluding the cognitive therapy costs) were significantly lower in the cognitive therapy group (734) than in the control group (1,119). This was due to savings on inpatient admissions (161, 95% CI: 35 -356) and day-patient services (206, 95% CI: 54 -466).
Cognitive therapy resulted in a mean cost-saving of 385 (95% CI: 1 -769; p<0.05).
When cognitive therapy costs were included, patients receiving cognitive therapy were 779 (95% CI: 387 -1,170; p<0.01) more costly than those receiving standard clinical treatment. However, the incremental cost incurred by these patients (779) was lower that the overall mean therapy cost of cognitive therapy (1,164).
Synthesis of costs and benefits
The incremental cost-effectiveness ratio (ICER) of cognitive therapy was 4,328 per relapse averted or 12.5 per additional relapse-free day. Based on the cost-effectiveness-acceptability curve for cognitive therapy, if the decisionmaker would be prepared to pay 6,000, the probability of cognitive therapy being cost-effective would be over 60%, and at 8,500, the probability would be over 80%. The ICER increased to 4,667 using the mean imputation method and
